This article is more than 5 years old. Information may no longer be current.
Lion TCR T-cell therapy for liver cancer to undergo phase 1/2 trial
Click Here to Manage Email Alerts
Lion TCR received approval from the Health Sciences Authority in Singapore to perform a phase 1/2 multicenter clinical study of its LioCyx candidate for treating liver cancer relapse after liver transplant, according to a press release.
“We are very delighted with the approval of phase 1/2 clinical trial of our LioCyx, the first engineered TCR T-cell therapy for treatment of liver cancer in Singapore,” Victor Li Lietao, MD, founder and CEO of Lion TCR, said in the release. “It is an utmost encouragement on the recognition of innovative therapy for patients in need. Singapore [Health Sciences Authority] has been very efficient, transparent and professional in reviewing our application for the clinical trial of this innovative immunotherapy.”
LioCyx is a precision T-cell receptor (TCR) immune cell therapy designed to target hepatitis B-related liver cancer. Lion TCR’s scientific founder, Antonio Bertoletti, MD, developed the therapy and several investigator-sponsored trials have shown good safety and efficacy profiles.
The phase 1/2 patient recruitment will begin with National University Hospital in Singapore before adding other centers from Singapore and China.
Reference: www.liontcr.com